Breast Cancer Res Treat;利用微卫星变异诊断乳腺癌

2014-07-11 佚名 生物谷

2014年7月10日讯 /生物谷BIOON/--抗击乳腺癌的战斗是没有止境的,近日,弗吉尼亚理工大学的研究人员发现一种新的诊断标志物,可能有助于临床医生更好地预测和预防这种疾病。 八分之一的妇女在有生之年可能患乳腺癌,因此找到更好的预测指标非常重要。通过将乳腺癌血液样品基因组与无癌症个人的样本进行比较,研究人员精确定位了一些新的标记,不仅可以揭示乳腺癌风险,同时可能为乳腺癌的治疗产生益处。这项

2014年7月10日讯 /生物谷BIOON/--抗击乳腺癌的战斗是没有止境的,近日,弗吉尼亚理工大学的研究人员发现一种新的诊断标志物,可能有助于临床医生更好地预测和预防这种疾病。

八分之一的妇女在有生之年可能患乳腺癌,因此找到更好的预测指标非常重要。通过将乳腺癌血液样品基因组与无癌症个人的样本进行比较,研究人员精确定位了一些新的标记,不仅可以揭示乳腺癌风险,同时可能为乳腺癌的治疗产生益处。这项研究结果发表在Breast Cancer Research and Treatment杂志上。

研究人员发现两组样本之间微卫星的微小变化,微卫星是基因组中重复DNA的小区域,可以以各种不同的方式影响细胞功能。通常在过去,微卫星被称为“垃圾DNA”,但目前认为微卫星在许多疾病和基因突变中是重要的。一般情况下,在细胞复制过程中,发生的基因突变被DNA修复机制清理,但不是所有的都是,一些突变可能导致癌症。

新一代测序技术和新的分析工具让科学家能更深入地探讨DNA的暗物质,这可能会产生比目前使用的更可靠的新的标记物,以及可能的基因疗法。利用微卫星变异诊断有可能改变癌症和其他遗传性疾病的诊断和治疗方式。

原始出处

McIver LJ1, Fonville NC, Karunasena E, Garner HR.Microsatellite genotyping reveals a signature in breast cancer exomes.Breast Cancer Res Treat. 2014 Jun

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078495, encodeId=947b20e8495aa, content=<a href='/topic/show?id=9cf9505582e' target=_blank style='color:#2F92EE;'>#微卫星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50558, encryptionId=9cf9505582e, topicName=微卫星)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Nov 29 11:05:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796236, encodeId=5ef11e962369e, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Tue Jul 29 02:05:00 CST 2014, time=2014-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710729, encodeId=c2371e107294e, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jan 26 07:05:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342306, encodeId=72e3134230649, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351056, encodeId=6c9c135105620, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=)]
    2014-11-29 qjddjq
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078495, encodeId=947b20e8495aa, content=<a href='/topic/show?id=9cf9505582e' target=_blank style='color:#2F92EE;'>#微卫星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50558, encryptionId=9cf9505582e, topicName=微卫星)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Nov 29 11:05:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796236, encodeId=5ef11e962369e, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Tue Jul 29 02:05:00 CST 2014, time=2014-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710729, encodeId=c2371e107294e, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jan 26 07:05:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342306, encodeId=72e3134230649, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351056, encodeId=6c9c135105620, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078495, encodeId=947b20e8495aa, content=<a href='/topic/show?id=9cf9505582e' target=_blank style='color:#2F92EE;'>#微卫星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50558, encryptionId=9cf9505582e, topicName=微卫星)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Nov 29 11:05:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796236, encodeId=5ef11e962369e, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Tue Jul 29 02:05:00 CST 2014, time=2014-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710729, encodeId=c2371e107294e, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jan 26 07:05:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342306, encodeId=72e3134230649, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351056, encodeId=6c9c135105620, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078495, encodeId=947b20e8495aa, content=<a href='/topic/show?id=9cf9505582e' target=_blank style='color:#2F92EE;'>#微卫星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50558, encryptionId=9cf9505582e, topicName=微卫星)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Nov 29 11:05:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796236, encodeId=5ef11e962369e, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Tue Jul 29 02:05:00 CST 2014, time=2014-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710729, encodeId=c2371e107294e, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jan 26 07:05:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342306, encodeId=72e3134230649, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351056, encodeId=6c9c135105620, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078495, encodeId=947b20e8495aa, content=<a href='/topic/show?id=9cf9505582e' target=_blank style='color:#2F92EE;'>#微卫星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50558, encryptionId=9cf9505582e, topicName=微卫星)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Nov 29 11:05:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796236, encodeId=5ef11e962369e, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Tue Jul 29 02:05:00 CST 2014, time=2014-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710729, encodeId=c2371e107294e, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jan 26 07:05:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342306, encodeId=72e3134230649, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351056, encodeId=6c9c135105620, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 13 00:05:00 CST 2014, time=2014-07-13, status=1, ipAttribution=)]
    2014-07-13 zhaojie88

相关资讯

JMCC:乳腺癌他莫昔芬耐药性可能与Snail/Slug信号有关

国际学术期刊Journal of Molecular Cell Biology在线发表了中国科学院上海生命科学研究院生物化学与细胞生物学研究所葛高翔研究组的最新研究成果 “Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR–ERK independen

CSMO 2014:乳腺癌抗HER-2耐药后的治疗策略

  在7月4日的第八届中国肿瘤内科大会会上,中国医学科学院肿瘤医院内科的李青教授介绍了乳腺癌">乳腺癌抗HER-2耐药后的治疗策略。人表皮生长因子受体2(Her-2)过表达是乳腺癌患者的一个独立预后因子。曲妥珠单抗是一种结合于Her-2蛋白细胞外域的人源化单克隆抗体,该药物在Her-2过表达的早期及晚期乳腺癌治疗中发挥了重要作用。然而,一些患者仍对曲妥珠单抗的抗Her-2治疗产生原发性或

英研究称简单血液测试可检测乳腺癌

据法国《观点报》6月30日报道,英国研究发现,一个简单的血液测试可预先10年发现是否患有乳腺癌。 报道称,一个简单的血液测试或许就可以挽救许多人的生命。法国国家健康与医学研究院指出,尽管近14年来,乳腺癌患者死亡率有所下降,但2010年,仍有1.15万名女性死于乳腺癌。不过,伦敦大学学院研究人员在《基因组医学》杂志中发表的科学研究成果或将大大降低这一数字。据研究人员称,一个简单的血液测试即可预先

BMJ:乳腺癌钼靶筛查利弊难评

瑞士医学委员会近期回顾了乳腺癌筛查的相关证据,并向瑞士政府提出建议。委员会指出,近期关于钼靶筛查的讨论主要基于过时的随机对照试验,并且没有显著证明钼靶筛查利大于弊。他们建议在瑞士不应再进行新的钼靶筛查项目,目前正在进行的项目也应逐渐淘汰。 瑞士医学委员会的建议依赖于另一专家组的结论:英国钼靶检查专家组。根据已经发表的随机对照试验结果,英国专家组发现,10000位被邀请在以后20年中接受检查的50

JNCI:靶向整合素αvβ6治疗乳腺癌

近日,伦敦大学玛丽皇后学院(QMUL)研究人员揭示了整合素αvβ6在帮助乳腺癌细胞生长和扩散的基础性作用。这项研究发表在Journal of the National Cancer Institute杂志上,精确定位了这个分子可作为治疗最积极类型乳腺癌的一个可行的新靶标。 有五分之一的乳腺癌患者是HER2阳性,HER2阳性是一个特别积极类型的乳腺癌,其中HER2蛋白水平升高促使癌细胞生长和扩散

JCI:DLC1调控乳腺癌细胞骨转移研究的新进展

国际著名学术期刊The Journal of Clinical Investigation在线发表了健康科学研究所胡国宏研究组与山东大学齐鲁医院杨其峰研究组合作完成的题为“DLC1-dependent parathyroid hormone - like hormone inhibition suppresses breast cancer bone metastasis”的最新研究成果。论文首次